No Data
No Data
Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Leerink Upgrades AN2 Therapeutics to Outperform Rating With $5 Price Target
Leerink Partners Upgrades AN2 Therapeutics to Outperform
Express News | Octagon Capital Advisors LP Reports 10.1% Passive Stake in AN2 Therapeutics as of June 13 - SEC Filing
Leerink Partners Upgrades AN2 Therapeutics(ANTX.US) to Buy Rating, Maintains Target Price $5
Optimistic Outlook for AN2 Therapeutics' Epetraborole Despite Initial Concerns
No Data
NVDAvsTSLA : No one knows the results only the company themselves
Trytosaveabit OP NVDAvsTSLA : That’s why I said ( upcoming ) meaning later when they release the results/data! If it’s good it could be a catalyst. Hehehe
NVDAvsTSLA Trytosaveabit OP : Agree. Back to $20 is easy once the tests are good
Trytosaveabit OP NVDAvsTSLA : That would be a great thing to see! GL to ya![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)